T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART)

Blood. 2000 Jan 1;95(1):249-55.

Abstract

In human immunodeficiency virus (HIV)-1 infection, highly increased T-cell turnover was proposed to cause exhaustion of lymphocyte production and consequently development of AIDS. Here, we investigated cell proliferation, as measured by expression of the Ki-67 nuclear antigen, in peripheral blood CD4(+) and CD8(+) lymphocyte subpopulations before and during highly active antiretroviral therapy (HAART). In untreated HIV-1 infection, both the percentage and number of Ki-67(+) CD4(+) and CD8(+) lymphocytes were significantly increased, compared with values obtained from healthy individuals. A more than 10-fold increase in the percentage of dividing naive CD4(+) T cells in the blood was found when the number of these cells were below 100 per microL. HAART induced an immediate decline in Ki-67 antigen expression, despite often very low CD4(+) T-cell numbers, arguing against increased proliferation being a homeostatic response. After approximately 24 weeks of HAART treatment, a transient increase in the number of proliferating cells was seen, but only in the CD4(+) CD27(+) memory pool. In the CD8(+) T-cell compartment, the number of dividing cells was elevated 20- to 25-fold. This increase was most notable in the CD27(+) CD 45RO(+) and CD27(-) CD45RO(+) memory CD8(+) T-cell pool, corresponding with the degree of expansion of these subsets. Reduction of plasma HIV-RNA load by HAART was accompanied by a decrease in numbers and percentages of dividing cells in all CD8(+) T-cell subsets. Taken together, our results indicate that peripheral T-cell proliferation is a consequence of generalized immune activation. (Blood. 2000;95:249-255)

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Multicenter Study

MeSH terms

  • Anti-HIV Agents / therapeutic use*
  • Antigens, CD / blood*
  • CD4-Positive T-Lymphocytes / immunology
  • CD8-Positive T-Lymphocytes / immunology
  • Drug Therapy, Combination
  • HIV Infections / drug therapy*
  • HIV Infections / immunology*
  • HIV Seronegativity / immunology
  • HIV-1 / immunology*
  • Humans
  • Indinavir / therapeutic use
  • Ki-67 Antigen / immunology
  • Lamivudine / therapeutic use
  • Longitudinal Studies
  • Lymphocyte Activation*
  • RNA, Viral / blood
  • Saquinavir / therapeutic use
  • T-Lymphocyte Subsets / immunology*
  • T-Lymphocytes / classification
  • T-Lymphocytes / immunology*
  • Viral Load
  • Zidovudine / therapeutic use

Substances

  • Anti-HIV Agents
  • Antigens, CD
  • Ki-67 Antigen
  • RNA, Viral
  • Lamivudine
  • Zidovudine
  • Indinavir
  • Saquinavir